Condition: Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere · Systemic Sclerosis Pulmonary · Dermatomyositis · Sponsor: Oslo University Hospital
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology. It is planned as a 2 arm 54 week multi-centre randomised controlled trial to assess outcome of home monitoring with bi-weekly serial forced vital capacity- and patient reported outcome-measurements compared to standard of care with fixed-interval hospital visits in adult patients with rheumatic disease associated interstitial lung diseases.
This description comes directly from the study's public registry record.
Emily V Langballe, MD · 0047 2307 0000 · emilylangballe@hotmail.com
Peter M Andel, MD, Dr.med. · 0047 2307 0000 · pemian@ous-hf.no
Always discuss trial participation with your own doctor first.
| Oslo University Hospital | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732674